Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Champions Oncolog (NQ: CSBR )

4.400 -0.150 (-3.30%)
Streaming Delayed Price Updated: 10:35 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Champions Oncolog

< Previous 1 2 Next >
Champions Oncology Announces Agreement with Weill Cornell Medicine
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Via ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Via ACCESSWIRE
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $13.1 Million
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Via ACCESSWIRE
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.0 Million
Via ACCESSWIRE
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
Via ACCESSWIRE
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $11.6 Million
Via ACCESSWIRE
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023
Via ACCESSWIRE
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
Via ACCESSWIRE
Champions Oncology Announces the Addition of Brady Davis as President
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.6 Million
Via ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023
Via ACCESSWIRE
Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
Via ACCESSWIRE
Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies
Via ACCESSWIRE
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023
Via ACCESSWIRE
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
Via ACCESSWIRE
Champions Oncology Announces $5M Stock Repurchase Program
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.8 Million
Via ACCESSWIRE
Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023
Via ACCESSWIRE
Champions Oncology Reports Record Quarterly Revenue of $14.3 Million
Via ACCESSWIRE
Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022
Via ACCESSWIRE
Champions Oncology Reports Record Quarterly Revenue of $13.7 Million
Via ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022
Via ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Record Annual Revenue of $49.1 Million 
From Champions Oncology, Inc.
Via AccessWire
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022
HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven... 
From Champions Oncology, Inc.
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.